Baozhen D. Ma

127 Dong Ming Road
Zhengzhou, 450003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Solitary intracranial metastasis as the sole relapse site in gastric cancer patients after neoadjuvant therapy and surgery: a case series of 12 patients and clinical implications.

Solitary intracranial metastasis as the sole relapse site in gastric cancer patients after neoadjuvant therapy and surgery: a case series of 12 patients and clinical implications.

Journal: Frontiers in oncology

Published: March 25, 2026

Predictors of postoperative recurrence in locally advanced gastric cancer patients achieving pathological complete response after neoadjuvant therapy: a matched case-control study.

Predictors of postoperative recurrence in locally advanced gastric cancer patients achieving pathological complete response after neoadjuvant therapy: a matched case-control study.

Journal: Frontiers in oncology

Published: October 02, 2025

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis.

The baseline circulating immunophenotype characteristics associate with PD(L)-1 targeted treatment response, irae onset, and prognosis.

Journal: Scientific reports

Published: February 27, 2025

Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy.

Impact of Tregs on tumor regression in locally advanced G/GEJ cancer patients undergoing neoadjuvant chemoimmunotherapy.

Journal: Scientific reports

Published: August 30, 2024

Tongue squamous cell carcinoma treated by 5-aminolevulinic acid administrated through Microdrop method.

Tongue squamous cell carcinoma treated by 5-aminolevulinic acid administrated through Microdrop method.

Journal: Photodiagnosis and photodynamic therapy

Published: June 08, 2024

The efficacy of subsequent therapy after failure of anti-PD-1 antibody in metastatic renal cell carcinoma.

The efficacy of subsequent therapy after failure of anti-PD-1 antibody in metastatic renal cell carcinoma.

Journal: Translational cancer research

Published: December 28, 2023

Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma.

Neoadjuvant chemoimmunotherapy in locally advanced gastric or gastroesophageal junction adenocarcinoma.

Journal: Frontiers in oncology

Published: November 21, 2023

The inter-link of ageing, cancer and immunity: findings from real-world retrospective study.

The inter-link of ageing, cancer and immunity: findings from real-world retrospective study.

Journal: Immunity & ageing : I & A

Published: June 10, 2023

Immune-related pneumonitis requiring low-dose prednisone maintenance in one patient with durable complete response.

Immune-related pneumonitis requiring low-dose prednisone maintenance in one patient with durable complete response.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: September 19, 2022

Complete remission of ovarian clear cell carcinoma achieved after pseudoprogression during PD-1 inhibitor therapy.

Complete remission of ovarian clear cell carcinoma achieved after pseudoprogression during PD-1 inhibitor therapy.

Journal: Immunotherapy

Published: August 31, 2022

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer.

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer.

Journal: Frontiers in oncology

Published: January 11, 2022

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study.

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study.

Journal: Frontiers in immunology

Published: September 18, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026